Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer

作者：Gloeckner Sabine C; Dhir Mashaal; Yi Joo Mi; McGarvey Kelly E; Van Neste Leander; Louwagie Joost; Chan Timothy A; Kleeberger Wolfram; de Bruine Adriaan P; Smits Kim M; Bakker Carolina A J Khalid de; Jonkers Daisy M A E; Stockbruegger Reinhold W; Meijer Gerrit A; Oort Frank A; Iacobuzio Donahue Christine; Bierau Katja; Herman James G; Baylin Stephen B; Van Engeland Marion; Schuebe Kornel E; Ahuja Nita^*

来源：Cancer Research, 2009, 69(11): 4691-4699.

DOI：10.1158/0008-5472.CAN-08-0142

We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future. [Cancer Res 2009;69(11):4691-9]

• 出版日期2009-6-1